Described herein are pet food compositions comprising—in relevant part—effective amounts of betaine and carnitine. Methods of making and using these compositions are also described.

Described herein are pet food compositions comprising—in relevant part—effective amounts of betaine and carnitine. Methods of making and using these compositions are also described.

The present disclosure generally relates to various formulations and uses of the compound: N-(heptan-4-yl)benzo[d] [1,3]dioxole-5-carboxamide, which is also referred to herein a “TM1” and comestibly acceptable salts thereof. In some aspects, the disclosure provides compositions that include TM1, or a comestibly acceptable salt thereof. In some embodiments, the compositions are ingestible compositions, including, but not limited to, packaged food and beverage products. In some other aspects, the disclosure provides methods of reducing the caloric content of a flavored article, for example, by reducing the amount of caloric sweeteners, fatty products (such as cheese). In some other aspects, the disclosure provides methods of reducing the amount of monosodium glutamate (MSG).

The present disclosure generally relates to various formulations and uses of the compound: N-(heptan-4-yl)benzo[d] [1,3]dioxole-5-carboxamide, which is also referred to herein a “TM1” and comestibly acceptable salts thereof. In some aspects, the disclosure provides compositions that include TM1, or a comestibly acceptable salt thereof. In some embodiments, the compositions are ingestible compositions, including, but not limited to, packaged food and beverage products. In some other aspects, the disclosure provides methods of reducing the caloric content of a flavored article, for example, by reducing the amount of caloric sweeteners, fatty products (such as cheese). In some other aspects, the disclosure provides methods of reducing the amount of monosodium glutamate (MSG).

The present invention relates to a composition for preventing or treating ischemia-reperfusion injury, the composition comprising an NADPH oxidase 1 (NOX1) inhibitor as an active ingredient, and more specifically, to a composition exhibiting prophylactic or therapeutic effects on ischemia reperfusion injury by suppressing the signaling of extracellular-signal-regulated kinase (ERK) by means of reactive oxygen species (ROS).

Disclosed embodiments provide nutritional compositions and methods of enhancing maturation of an infant's brain. The methods include the step of administering to the infant a nutritional composition comprising a protein with a degree of hydrolysis of 10% to 75% in combination with at least one of a monoglyceride, a free fatty acid, a salt of a free fatty acid, a phospholipid, and cholesterol.

The present invention provides combinations comprising a sedating antihistamine and selected indole-based natural products such as L-tryptophan, 5-hydroxytryptophan and melatonin, along with pharmaceutically acceptable calcium and magnesium salts and selected B vitamins. These combinations are useful in providing a medicament for improving sleep in mammals, especially humans.

The present invention relates to a composition comprising gossypetin or a salt thereof for prevention or treatment of neurodegenerative disease. Having an excellent prophylactic and therapeutic effect on neurodegenerative disease and excellently improving memory and cognitive functions, the composition of the invention can be advantageously used not only for preventing and treating neurodegenerative disease, but also for improving memory and cognitive function.

The present invention relates to a composition comprising gossypetin or a salt thereof for prevention or treatment of neurodegenerative disease. Having an excellent prophylactic and therapeutic effect on neurodegenerative disease and excellently improving memory and cognitive functions, the composition of the invention can be advantageously used not only for preventing and treating neurodegenerative disease, but also for improving memory and cognitive function.

The invention relates to formula comprising a combination of urea and non-digestible oligosaccharides, for improved stimulation of the growth of Bifidobacteria in the intestinal microbiota of infants or young children.